Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 11, 2016 - Issue
Submit an article Journal homepage
110
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting

Valentina PerroneCliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, Italy
,
Diego SangiorgiCliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, Italy
,
Stefano BudaCliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, Italy
&
Luca Degli EspostiCliCon S.r.l. Health, Economics and Outcomes Research, Ravenna, ItalyCorrespondence[email protected]
Pages 2749-2755 | Published online: 04 Nov 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Paolo Solidoro, Filippo Patrucco & Diego Bagnasco. (2019) Comparing a fixed combination of budesonide/formoterol with other inhaled corticosteroid plus long-acting beta-agonist combinations in patients with chronic obstructive pulmonary disease: a review. Expert Review of Respiratory Medicine 13:11, pages 1087-1094.
Read now

Articles from other publishers (7)

Ralph Brattsand & Olof Selroos. (2022) May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide?. Pulmonary Pharmacology & Therapeutics 77, pages 102167.
Crossref
A.L. Aguilar-Shea & C. Gallardo-Mayo. (2022) Revisión narrativa de la terapia inhalatoria en la EPOC. Medicina de Familia. SEMERGEN 48:3, pages 214-218.
Crossref
Meng-Ting Wang, Jyun-Heng Lai, Ya-Ling Huang, Jun-Ting Liou, Shih-Hsuan Cheng, Chen Wei Lin, Hsueh-Yi Pan, Yu-Juei Hsu & Chen-Liang Tsai. (2021) Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β2-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting β2-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study. Chest 160:4, pages 1255-1270.
Crossref
Pinar Yildiz, Mesut Bayraktaroglu, Didem Gorgun & Kivanc Yuksel. (2019) Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair® in Adult Patients with Moderate-to-Severe Stable COPD: Open-Label, Single-Arm, Phase IV Trial. Clinical Drug Investigation 39:10, pages 991-1001.
Crossref
Cheng-Yi Wang, You Shuei Lin, Ya-Hui Wang, Chih-Cheng Lai, Hao-Chien Wang, Likwang Chen & Chong-Jen Yu. (2019) Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists. Aging 11:17, pages 6863-6871.
Crossref
A.L. Aguilar-Shea. (2018) EPOC, ¿cuál es el mejor tratamiento?. Medicina de Familia. SEMERGEN 44:7, pages 523-524.
Crossref
Debra Siela. (2018) Acute respiratory failure and COPD. Nursing Critical Care 13:1, pages 28-37.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.